Copied
 
 
Formål
Formål
Selskabets formål er at udøve virksomhed indenfor udvikling af lægemidler og anden virksomhed i forbindelse hermed.
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Ingen historik.
Branche
Branche
Forskning og eksperimentel udvikling indenfor bioteknologi (721100).
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Ingen historik.
Revision
Revisionfravalgt
false.
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Ingen historik.
Revisor
Revisor
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
Sidst opdateret den 21.12.2023 og angivet som gældende fra 15.12.2023 (345 dage).
Form
Virksomhedsform
80.
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Ingen historik.
Kontakt
Kontaktoplysninger
tn@nordicbio.com.
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Ingen historik.
Telefon
Telefonnummer
44547705.
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Ingen historik.
Navne
Ingen historik.
Tegningsregel
Tegningsregel
Selskabet tegnes af en direktør.
Sidst opdateret den 09.10.2019 og angivet som gældende fra 08.10.2019 (1874 dage).
Fortolkning (1 tegningsmulighed)
1 direktør
Ingen historik.
Ansatte
24.11.2024
Ingen historik.
Kapital
24.11.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33771231
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Management has prepared the Annual Report under the assumption of going concern. The balance sheet shows net current liabilities of 289 mDKK. The Company has not provided us with documentation indicating that the Company has sufficient funds, or will receive additional financial funds from shareholders, in order to be able to pay the current liabilities once they are due. Based on the above, there is considerable doubt about the going concern assumption for the Company. Our conclusion is adverse regarding this assumption. We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the ”Auditor’s responsibilities for the audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our adverse opinion.
Konklusion (revision):In our opinion, because of the significance of the matters discussed in the Basis for adverse opinion paragraph, the Financial Statements do not give a true and faie view of the financial position of the Company at 31 December 2023 and of the results of the Company´s operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act. We have audited the Financial Statements of Symic OA ApS for the financial year 1 January - 31 December 2023, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies (”the Financial Statements”).
Udtalelse om ledelsesberetningen (revision):Management is responsible for Management’s Review. Our opinion on the Financial Statements døs not cover Management’s Review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the Financial Statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financial Statements Act. As the Basis for Adverse Opinion section shows, we express a modified opinion on the Financial Statements due to the doubt about the going concern assumption. We conclude, for the same reason, that Management’s Review is not free from material misstatement in relation to the amounts and other elements affected by the going concern assumption.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
24.11.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
24.11.2024
Ingen nuværende registrering.
Ingen historik.